Holen Sie sich die Stockscreener-App
1.20
0.83%
-0.01
Vorhandelsmarkt:
1.20
Milestone Pharmaceuticals Inc Aktie (MIST) Neueste Nachrichten
Milestone Pharma's nasal spray gets first ex-US approval - The Pharma Letter
Milestone Pharmaceuticals Inc. (MIST) Shareholding Pattern – Promoters, FIIs & DIIs - Value Research
MIST Reiterated by HC Wainwright & Co. -- Price Target Maintained at $8.00 - GuruFocus
Milestone Pharmaceuticals (MIST) Gains China Approval for Etripa - GuruFocus
Milestone Pharmaceuticals Says NMPA Approval Triggers $2 Mln Milestone Payment To The Co - TradingView
Milestone Pharmaceuticals Announces NMPA Approval of Etripamil Nasal Spray for PSVT in China, Marking First Regulatory Approval of Etripamil Outside of the United States - Yahoo Finance
Milestone Pharmaceuticals Inc. (MIST) Key Financial Ratios – Valuation, Profitability & More - Value Research
Milestone Pharmaceuticals to Present at Upcoming Investor Conferences - The Manila Times
Three investor events are set for Boston and New York, with Milestone joining - Stock Titan
Milestone Pharmaceuticals stock holds at $1.16 as fundamentals and outlook stay in focus - AD HOC NEWS
Milestone Pharmaceuticals Inc. (MIST) Financials – Balance Sheet, Profit & Loss, Cash Flow - Value Research
Milestone presents study on PSVT impact between episodes By Investing.com - Investing.com Canada
Milestone Pharmaceuticals Announces Data Presented at ESC Congress 2026 on the Impact of Paroxysmal Supraventricular Tachycardia (PSVT) on Patients’ Daily Lives and Quality of Life Between Episodes - GlobeNewswire
Milestone presents study on PSVT impact between episodes - Investing.com
First Patient Enrolled in the Phase 3 ReVeRA-301 Pivotal Trial for Afib - dicardiology.com
Milestone’s etripamil nasal spray enters Phase III trial for atrial fibrillation - Yahoo
Milestone (MIST) Results Breakdown: EPS Comes in Below Forecast in Latest Trading; Latest Reaction: The Stock Records a 2.43% Increase for the Current SessionFree Cash Flow Trends - vinanet.vn
Milestone Pharmaceuticals (NASDAQ:MIST) Advances Trial Path - Kalkine Media
Milestone Pharmaceuticals begins phase 3 trial for AFib treatment By Investing.com - Investing.com Nigeria
Milestone Pharmaceuticals shares rise as first patient enters Phase 3 AFib trial - Yahoo Finance
Milestone Pharmaceuticals (MIST) Launches Phase 3 Trial Amidst High Price-to-Sales Valuation - GuruFocus
Milestone Pharmaceuticals stock gains on Phase 3 AFib trial By Investing.com - Investing.com South Africa
Milestone Pharmaceuticals stock gains on Phase 3 AFib trial - Investing.com
Milestone Pharmaceuticals begins phase 3 trial for AFib treatment - Investing.com
Milestone Pharmaceuticals Enrolls First Patient in Phase 3 ReVeRA-301 Trial of Etripamil for AFib-RVR - Quiver Quantitative
Milestone Pharmaceuticals Initiates Pivotal Phase 3 Trial of Etripamil Nasal Spray for Self-Administered Treatment of Atrial Fibrillation with Rapid Ventricular Rate (AFib-RVR) - The Manila Times
This Sphere Entertainment Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday - Sahm
Cantor Fitzgerald initiates Milestone Pharmaceuticals stock coverage with overweight rating - Investing.com Canada
MIST Initiated Coverage by Cantor Fitzgerald -- Rating Overweight - GuruFocus
Milestone Pharmaceuticals: Reiterating Sell As The Losses Compound (NASDAQ:MIST) - Seeking Alpha
Milestone Pharmaceuticals (MIST) Climbs 2.8% as Shares Hold Above $1.04 SupportShort Setup Alerts - vinanet.vn
Milestone’s FDA Win Now Faces A Tougher Test: Sales - Finimize
What is HC Wainwright's Forecast for MIST Q3 Earnings? - MarketBeat
TD Cowen Maintains Milestone Pharmaceuticals(MIST.US) With Buy Rating, Maintains Target Price $8 - Moomoo
Earnings To Watch: Milestone Scientific Inc (MLSS) Q2 2026 -- GF Value Sees 13% Upside - finance.yahoo.com
What is HC Wainwright's Estimate for MIST FY2028 Earnings? - MarketBeat
Wells Fargo Maintains Milestone Pharmaceuticals(MIST.US) With Buy Rating, Maintains Target Price $7 - Moomoo
Milestone Pharmaceuticals earnings missed by $0.02, revenue topped estimates - Investing.com Canada
Milestone Pharmaceuticals Inc. Q2 2026 Earnings Call Summary - Yahoo Finance
Milestone Pharmaceuticals (NASDAQ:MIST) Releases Earnings Results, Misses Expectations By $0.01 EPS - MarketBeat
Milestone Pharmaceuticals Releases Q2 2026 Financial Results - AlphaStreet
Milestone Pharmaceuticals Q2 Earnings Call Highlights - MarketBeat
Milestone Pharmaceuticals Q2 Results: Net loss widens to $28.6M - scanx.trade
Milestone Pharmaceuticals Inc (MIST) Stock Forecast, Price Targets and Analysts Predictions - GuruFocus
Milestone Pharmaceuticals Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Earnings call transcript: Milestone posts Q2 loss as CARDAMYST launch gains traction - Investing.com
Q2 2026 Milestone Pharmaceuticals Inc Earnings Call Transcript - GuruFocus
Form 8K MILESTONE PHARMACEUTICALS INC. For: 12 August By Investing.com - Investing.com South Africa
Milestone Pharmaceuticals (MIST) Reports Q2 Loss, Lags Revenue Estimates - Yahoo Finance
Milestone Pharmaceuticals shares tumble after Q2 earnings miss - Yahoo Finance
Milestone Pharmaceuticals stock tumbles 12% on Q2 earnings miss By Investing.com - Investing.com Nigeria
Milestone Pharmaceuticals reports Q2 2026: $0.6M product revenue, $28.6M net loss, $170.6M cash - TradingView
Milestone Pharmaceuticals stock tumbles 12% on Q2 earnings miss - Investing.com
Milestone Pharmaceuticals: Q2 Earnings Snapshot - marketscreener.com
Milestone Pharmaceuticals Announces Second Quarter 2026 Financial Results and Provides Corporate Update - The Manila Times
Milestone Pharmaceuticals Inc. Q2 2026: Revenue $0.6M, EPS $(0.21) — 10-Q Summary - TradingView
Press Release: Milestone Pharmaceuticals Announces Second Quarter 2026 Financial Results and Provides Corporate Update - Moomoo
What To Expect From Milestone Pharmaceuticals Inc (MIST) Q2 2026 Earnings - Yahoo Finance
0.86%
0.31%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):